Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease.
作者信息
Lin Chuan-Hao, Kohli Rohit
机构信息
Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital Los Angeles, and the Department of Pediatrics Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
出版信息
Clin Transl Gastroenterol. 2018 Jun 29;9(6):164. doi: 10.1038/s41424-018-0034-3.
Abstract
摘要
相似文献
1
Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease.胆汁酸代谢与信号传导：非酒精性脂肪性肝病的潜在治疗靶点
Clin Transl Gastroenterol. 2018 Jun 29;9(6):164. doi: 10.1038/s41424-018-0034-3.
2
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.胆汁酸在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
3
Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.胆汁酸调控肥胖、2 型糖尿病、血脂异常和非酒精性脂肪性肝病中的代谢和炎症。
Gastroenterology. 2017 May;152(7):1679-1694.e3. doi: 10.1053/j.gastro.2017.01.055. Epub 2017 Feb 15.
4
Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.胆汁酸在非酒精性脂肪性肝病中的作用：新概念和治疗进展。
Ann Hepatol. 2017 Nov;16(Suppl. 1: s3-105.):s58-s67. doi: 10.5604/01.3001.0010.5498.
5
Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?核受体：它们在非酒精性脂肪性肝病治疗中处于何种地位？
Liver Int. 2014 Oct;34(9):1291-4. doi: 10.1111/liv.12578.
6
Role of Bile Acids in Metabolic Control.胆汁酸在代谢控制中的作用。
Trends Endocrinol Metab. 2018 Jan;29(1):31-41. doi: 10.1016/j.tem.2017.11.002. Epub 2017 Nov 28.
7
Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease.生物调节剂重塑胆汁酸池以治疗非酒精性脂肪性肝病。
Clin Sci (Lond). 2023 Jan 13;137(1):65-85. doi: 10.1042/CS20220697.
8
Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.使用法尼醇X受体激动剂治疗非酒精性脂肪性肝病。
Dig Dis. 2015;33(3):426-32. doi: 10.1159/000371698. Epub 2015 May 27.
9
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.胆汁酸与非酒精性脂肪性肝病：分子见解与治疗前景
Hepatology. 2017 Jan;65(1):350-362. doi: 10.1002/hep.28709. Epub 2016 Aug 4.
10
The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation.回肠胆汁酸转运体抑制剂A4250通过中断肠肝循环降低血清胆汁酸水平。
Aliment Pharmacol Ther. 2016 Jan;43(2):303-10. doi: 10.1111/apt.13457. Epub 2015 Nov 2.
引用本文的文献
1
Gut-Microbiota-Driven Lipid Metabolism: Mechanisms and Applications in Swine Production.肠道微生物群驱动的脂质代谢：机制及其在养猪生产中的应用
Metabolites. 2025 Apr 4;15(4):248. doi: 10.3390/metabo15040248.
2
Quantitative proteomics analysis based on data-independent acquisition reveals the effect of Shenling Baizhu powder (SLP) on protein expression in MAFLD rat liver tissue.基于数据非依赖采集的定量蛋白质组学分析揭示了参苓白术散（SLP）对非酒精性脂肪性肝炎（MAFLD）大鼠肝组织蛋白质表达的影响。
Clin Proteomics. 2023 Dec 1;20(1):55. doi: 10.1186/s12014-023-09442-9.
3
Hepatic Clstn3 Ameliorates Lipid Metabolism Disorders in High Fat Diet-Induced NAFLD through Activation of FXR.肝脏中的Clstn3通过激活法尼醇X受体（FXR）改善高脂饮食诱导的非酒精性脂肪性肝病（NAFLD）中的脂质代谢紊乱。
ACS Omega. 2023 Jul 12;8(29):26158-26169. doi: 10.1021/acsomega.3c02347. eCollection 2023 Jul 25.
4
Hepatoprotection of Probiotics Against Non-Alcoholic Fatty Liver Disease : A Systematic Review.益生菌对非酒精性脂肪性肝病的肝保护作用：一项系统评价
Front Nutr. 2022 Apr 11;9:844374. doi: 10.3389/fnut.2022.844374. eCollection 2022.
5
The roles of microbial products in the development of colorectal cancer: a review.微生物产物在结直肠癌发展中的作用：综述。
Bioengineered. 2021 Dec;12(1):720-735. doi: 10.1080/21655979.2021.1889109.
6
bile salt hydrolase substrate specificity governs bacterial fitness and host colonization.胆汁盐水解酶的底物特异性决定了细菌的适应性和宿主的定殖能力。
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6). doi: 10.1073/pnas.2017709118.
7
Nonalcoholic fatty liver disease and cardiovascular disease phenotypes.非酒精性脂肪性肝病与心血管疾病表型
SAGE Open Med. 2020 Jun 20;8:2050312120933804. doi: 10.1177/2050312120933804. eCollection 2020.
8
Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease.对抗非酒精性脂肪性肝病的当前及未来治疗方法
Cancers (Basel). 2020 Jun 28;12(7):1714. doi: 10.3390/cancers12071714.
9
Microbial Metabolites Determine Host Health and the Status of Some Diseases.微生物代谢物决定宿主健康和某些疾病的状态。
Int J Mol Sci. 2019 Oct 24;20(21):5296. doi: 10.3390/ijms20215296.
10
Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview.非酒精性脂肪性肝病的病理生理学、分子和治疗问题概述。
Int J Mol Sci. 2019 Apr 20;20(8):1948. doi: 10.3390/ijms20081948.
本文引用的文献
1
Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.FGF19/FGF15 对肝癌发生和代谢的鼠种特异性控制。
J Hepatol. 2017 Jun;66(6):1182-1192. doi: 10.1016/j.jhep.2017.01.027. Epub 2017 Feb 9.
2
Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.抑制回肠胆汁酸摄取可预防高脂饮食喂养小鼠的非酒精性脂肪性肝病。
Sci Transl Med. 2016 Sep 21;8(357):357ra122. doi: 10.1126/scitranslmed.aaf4823.
3
Fibroblast growth factor 21 correlates with weight loss after vertical sleeve gastrectomy in adolescents.成纤维细胞生长因子21与青少年垂直袖状胃切除术后体重减轻相关。
Obesity (Silver Spring). 2016 Nov;24(11):2377-2383. doi: 10.1002/oby.21658. Epub 2016 Sep 12.
4
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.胆汁酸与非酒精性脂肪性肝病：分子见解与治疗前景
Hepatology. 2017 Jan;65(1):350-362. doi: 10.1002/hep.28709. Epub 2016 Aug 4.
5
The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health.非酒精性脂肪性肝病的全球化：患病率及其对全球健康的影响。
Hepatology. 2016 Jul;64(1):19-22. doi: 10.1002/hep.28524. Epub 2016 Apr 4.
6
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.全球非酒精性脂肪性肝病流行病学——患病率、发病率和结局的荟萃分析评估。
Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
7
Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules.胆汁酸受体的药理学：从简单去污剂到复杂信号分子的胆汁酸演变
Pharmacol Res. 2016 Feb;104:9-21. doi: 10.1016/j.phrs.2015.12.007. Epub 2015 Dec 17.
8
Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.使用法尼醇X受体激动剂治疗非酒精性脂肪性肝病。
Dig Dis. 2015;33(3):426-32. doi: 10.1159/000371698. Epub 2015 May 27.
9
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.法尼醇X核受体配体奥贝胆酸治疗非肝硬化、非酒精性脂肪性肝炎（FLINT）：一项多中心、随机、安慰剂对照试验
Lancet. 2015 Mar 14;385(9972):956-65. doi: 10.1016/S0140-6736(14)61933-4. Epub 2014 Nov 7.
10
The role of small heterodimer partner in nonalcoholic fatty liver disease improvement after sleeve gastrectomy in mice.小异二聚体伴侣在小鼠袖状胃切除术后非酒精性脂肪性肝病改善中的作用。
Obesity (Silver Spring). 2014 Nov;22(11):2301-11. doi: 10.1002/oby.20890.
Zotero 插件